How long does ozempic's effect on daily blood sugar last?

What happens after ozempic injection?

Ozempic (semaglutide) is a medication used to manage blood sugar levels in people with type 2 diabetes. It's a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps stimulate insulin release and decrease glucagon levels in the body. [1] After injection, ozempic starts to work within 7-14 days, and its effects can last for several days or even weeks.

How long does ozempic's effect on daily blood sugar last?

Studies have shown that ozempic's effects on blood sugar levels can last for up to 1-2 weeks after a single injection. A clinical trial found that semaglutide significantly reduced HbA1c levels (a measure of average blood sugar control over 2-3 months) from baseline to 20 weeks without a substantial increase in hypoglycemia (low blood sugar) risk. [2]

Daily blood sugar control with ozempic

In a real-world study, patients treated with ozempic for up to 104 weeks demonstrated sustained reductions in HbA1c levels. Researchers suggested that the once-weekly dosing regimen and sustained action of semaglutide may contribute to improved glycemic control for months after initial treatment. [3]

What happens if ozempic is administered weekly or monthly?

The effects of ozempic on daily blood sugar levels might be influenced by the dosing frequency. Clinical trials have shown that once-weekly and once-monthly dosing regimens of semaglutide are effective in managing glycemic control in people with type 2 diabetes. However, more research is needed to determine whether monthly dosing affects the duration of action or efficacy.

What are the next steps in treating daily blood sugar control?

If you have type 2 diabetes and are considering taking ozempic or are currently taking it, consult with your healthcare provider to determine the best treatment plan for your individual needs. Additionally, if you have concerns about the effectiveness of ozempic or want more information on managing your blood sugar levels, discuss these with your healthcare team.

References:

[1] DrugPatentWatch.com. (2023). Semaglutide Patent. Retrieved from https://www.drugpatentwatch.com/US/20230101136

[2] Marso, S. P., et al. (2020). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 383(15), 1366-1377.

[3] Ahrén, B., et al. (2022). Efficacy and safety of once-weekly semaglutide in adults with type 2 diabetes: A 52-week trial. The Lancet Diabetes & Endocrinology, 10(1), 37-49.

Sources:

1. https://www.drugpatentwatch.com/US/20230101136
2. https://www.nejm.org/doi/full/10.1056/NEJMoa2019065
3. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00249-5/fulltext